Phase 2 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with high-risk multiple myeloma (identified by specific genetic markers — del17p, t(4;14), t(14;16), or 1q21 — found through a FISH test) or multiple myeloma that has spread outside the bone marrow.
• People between 18 and 70 years old (inclusive), of any gender.
• People with a general physical health score of 0–2 on a standard medical scale (ECOG), meaning they are fully active to mildly limited in daily activity (confirm with trial site).
• People with an expected life expectancy of at least 3 months.
• People with measurable signs of the disease, such as tumours outside the bone marrow measuring 1.0 cm or more, or certain levels of abnormal proteins detected in blood or urine tests.
• People whose routine blood test results meet specific minimum levels for white blood cells, platelets, and haemoglobin, with some flexibility allowed depending on how much of the bone marrow is affected by the disease (confirm with trial site).
• People whose liver and kidney function blood test results fall within acceptable ranges as defined by the trial.
• People who have received localised radiotherapy for pain relief or nerve compression, as long as the last radiotherapy treatment was more than 4 weeks before joining the trial.
• People who have read and signed the trial's informed consent form.

Who may not be able to join:

• People with significant heart problems, including a heart attack or viral heart inflammation within the past 6 months, unstable chest pain, heart failure, irregular heartbeat, valve disease, or ongoing heart muscle disease.
• People whose heart electrical activity test (ECG) shows a QTc interval greater than 480ms, or who have a condition called long QTc syndrome.
• People whose heart pumping function (ejection fraction) is below 50% or below the normal range used at the trial site.
• People with an active hepatitis B or hepatitis C infection, based on specific virus levels detected in blood tests.
• People who are HIV positive.
• People with an uncontrolled bacterial, fungal, or viral infection requiring full-body (systemic) treatment in the week before starting the trial medication.
• Women who are pregnant or breastfeeding.
• People who already have nerve damage or nerve-related pain rated at grade 2 or higher before starting treatment.
• People who have received systemic chemotherapy within the 28 days before their first trial dose.
• People with relapsed disease who previously did not respond to a medicine called pomalidomide, or who are not able to receive pomalidomide treatment.

Important: Always verify eligibility with the trial site directly before applying.